Cryptococcosis is a potentially fatal fungal infection caused by the fungus Cryptococcus. Factors such as the increase in the prevalence of fatal fungal diseases, rising treatment awareness, and last-stage HIV patients developing the disease are driving the growth of the cryptococcosis market worldwide.
The report titled “Cryptococcosis Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall Cryptococcosis market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on treatment type (Amphotericin B, Flucytosine, Fluconazole, and Other Treatment Options) and different geographical regions.
In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global cryptococcosis market, an attractive investment proposition, and the market positioning of key manufacturers.
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global cryptococcosis market.
Tools such as market positioning of key players and appealing investment propositions provide readers with insights into the global cryptococcosis market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global cryptococcosis market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global cryptococcal market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on treatment type, the global cryptococcosis market is segmented as follows:
- Amphotericin B
- Others (Voriconazole, surgery treatment, etc.)
Cryptococcosis is a disease caused by a species of fungus. Factors such as the increasing prevalence of fatal fungal diseases, advances in treatment options, and the fact that HIV-infected patients are at higher risk of developing fungal diseases are driving the growth of the cryptococcosis market worldwide.
Cryptococcus neoformans is the main cause of disease; it is rare among healthy individuals; however, it is a major cause of illness in HIV-infected patients. According to the Centers for Disease Control and Prevention (CDC), 1 million cases of cryptococcal meningitis occur among HIV-infected patients worldwide each year. In general, cryptococcosis treatment is divided into three stages: induction, consolidation, and maintenance.
During induction therapy, Amphotericin B and Flucytosine are the most commonly used treatment regimens on the market. Fluconazole and itraconazole are part of a treatment regimen given for at least eight weeks after the successful completion of 2 weeks of induction therapy. Fluconazole appears to be the preferred regimen for at least one year of maintenance therapy. Flucytosine was the leading revenue contributor in the global cryptococcosis market in 2016 due to factors such as the fact that Flucytosine is responsible for reducing fungal burden in the brain, spleen, and lungs and is also used as the first-line treatment for cryptococcosis infection.
For the purpose of this study, the global cryptococcosis market is categorized into three segments:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The major causes of cryptococcosis are infections by C. neoformans and C. gattii. It is observed that approximately 5 to 8% of HIV-infected patients in developed countries develop cryptococcosis. According to the Centers for Disease Control and Prevention (CDC), approximately 1 million cases of cryptococcal meningitis occur every year among patients infected with HIV.
In the base year 2016, North America dominated the cryptococcosis market in terms of revenue due to factors such as higher drug costs, an upsurge in funding by government agencies and private organizations in the healthcare system, an increase in the incidence of fungal infections in endemic areas of North America, and higher investments in research and development that are driving the market growth in North America.
Europe is the second largest revenue-generating region for the cryptococcal market because technological advances, developed healthcare infrastructure, and the higher cost of medication are influencing the market’s growth in Europe. Because the number of HIV-infected patients in the Middle East and Africa is extremely high, and there is an increase in demand for cryptococcal medication, the market is expected to grow significantly during the forecast period. However, factors such as the comparatively lower cost of treatment medication may hinder the growth of the cryptococcosis market in the Middle East and Africa.